Stock Ratings / Health Care / SANA / financials

DNA (28) GLUE (33) MGTX (27) FDMT (40) ⌘ Pro Terminal →

Sana Biotechnology Inc. (SANA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$2.72 +3.42% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.73

Sana Biotechnology Inc. (SANA) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $814.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.73 (+0.43%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SANA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (46/100 Composite)

🔍 WHY SANA SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (26% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (26% of score)

FRED Regime × Technicals: 15% of 52W Range • RSI-14 at 46.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$2.79-18.6% Next Q

Q2 (-2Q)

Grade C-$2.27+2.6% Next Q

Q3 (-1Q)

Grade D$2.33+16.7% Next Q

Current

Grade D$2.72-6.1% Hist 90D α

Trajectory: C- (54) → D (46)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SANA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SANA currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.04) and Max Pain ($2.86) forces dealer call-delta covering toward $5.76.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SANA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SANA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 46%NO 54%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How SANA Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-6.3%	-$244.2M	-$144.8M	-45%
FY 2024	$4.00B	52%	-6.8%	-$266.8M	-$256.6M	-45%
FY 2023	$4.00B	52%	-7.3%	-$283.3M	-$253.6M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SANA)

✓Walkthrough of SANA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SANA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -17.33%📐 HORIZONTAL RANGE

2026-10-30O $2.68H $2.72L $2.51C $2.72VOL 2.08M

RES: $4.23SUP: $2.09SMA50: $3.04SMA200: $3.39

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SANA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SANA Butterfly Map → + Track SANA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SANA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SANA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SANA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SANA)

Health Care Rank #447 of 1016 ⚔️ DNA vs SANA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SANA vs. DNA, GLUE, MGTX, FDMT)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Sana Biotechnology Inc. (SANA) ranks #447 by composite RQD confidence (46/100, grade D) and #385 by equity capitalization ($814.3M). Within this direct 5-issuer industry benchmark cohort, SANA leads on earnings valuation at N/A trailing P/E, while FDMT leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. SANA currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SANA ACTIVE Sana Biotechnology Inc.	D	46/100	—	—	-35.0%	+3.42%	$814.3M	Benchmark Subject
DNA Ginkgo Bioworks Holdings Inc. (Class A)	E	28/100	—	—	-35.0%	-4.35%	$819.7M	/dna-vs-sana →
GLUE Monte Rosa Therapeutics Inc.	E	33/100	—	—	-35.0%	+0.18%	$927.4M	/glue-vs-sana →
MGTX MeiraGTx Holdings plc	E	27/100	—	—	-35.0%	-0.46%	$932.1M	/mgtx-vs-sana →
FDMT 4D Molecular Therapeutics Inc.	D-	40/100	—	—	-28.3%	-1.16%	$706.0M	/fdmt-vs-sana →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001770121

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sana Biotechnology Inc. (SANA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$244.2M, operating cash flow of -$143.8M, and free cash flow of -$144.8M (+43.6% YoY). On the balance sheet, SANA closed FY2025 with $416.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$244.2M	-$143.8M	-$144.8M	$416.9M	—
FY2024 (FY)	2024-12-31	$0	-$266.8M	-$223.2M	-$256.6M	$501.0M	—
FY2023 (FY)	2023-12-31	$0	-$283.3M	-$253.6M	-$253.6M	—	—

3. SANA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SANA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Sana Biotechnology Inc. (NASDAQ: SANA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $2.72 (+3.42% 1D, market cap $814.3M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SANA ranks #447 in composite RQD confidence.

How does SANA compare to DNA and GLUE in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SANA carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DNA (Ginkgo Bioworks Holdings Inc. (Class A)) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $819.7M) and GLUE (Monte Rosa Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $927.4M). Among the 5-stock peer group, SANA leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SANA?

Per SANA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001770121), Sana Biotechnology Inc. generated $0 in revenue, -$244.2M in net income, and -$144.8M in free cash flow against $416.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SANA trading relative to its 50-day, 200-day, and 52-week technical levels?

SANA last traded at $2.72 (+3.42% on volume of 3,308,654 shares), positioning the stock -10.53% below its 50-day simple moving average ($3.04) and -19.76% below its 200-day simple moving average ($3.39). Across its 52-week range of $2.22 to $5.49, SANA sits at the 15.3% percentile with a 14-day RSI of 46.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.38 to $3.06).

SANA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Sana Biotechnology Inc. (SANA)?

In FY 2025 (10-K), SANA converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: SANA RQD Cockpit SANA 12M Forecast SANA Earnings & Move SANA Dividends & DRIP SANA Insiders & 13F SANA Whale Options SANA Profit Sankey SANA News & Why